pre-ipo
Stage
1
Investors
About
Gain Therapeutics develops allosteric small molecule therapeutics using AI-supported 3D structural biology and physics-based models, focusing on treatments for neurodegenerative diseases including GBA-linked Parkinson's disease, with its lead candidate GT-02287 currently in clinical trials.
Explore Gain Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.